HK1216002A1 - 治疗动脉瘤性蛛网膜下出血并发症的组合物及其用途 - Google Patents

治疗动脉瘤性蛛网膜下出血并发症的组合物及其用途 Download PDF

Info

Publication number
HK1216002A1
HK1216002A1 HK16103935.4A HK16103935A HK1216002A1 HK 1216002 A1 HK1216002 A1 HK 1216002A1 HK 16103935 A HK16103935 A HK 16103935A HK 1216002 A1 HK1216002 A1 HK 1216002A1
Authority
HK
Hong Kong
Prior art keywords
compositions
subarachnoid hemorrhage
aneurysmal subarachnoid
treat complications
brain injury
Prior art date
Application number
HK16103935.4A
Other languages
English (en)
Chinese (zh)
Inventor
R. Loch Macdonald
Original Assignee
Edge Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edge Therapeutics, Inc. filed Critical Edge Therapeutics, Inc.
Publication of HK1216002A1 publication Critical patent/HK1216002A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16103935.4A 2013-03-11 2014-03-11 治疗动脉瘤性蛛网膜下出血并发症的组合物及其用途 HK1216002A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/793,767 US10092524B2 (en) 2008-06-11 2013-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US201313793767 2013-03-11
PCT/US2014/023748 WO2014164904A1 (en) 2013-03-11 2014-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage

Publications (1)

Publication Number Publication Date
HK1216002A1 true HK1216002A1 (zh) 2016-10-07

Family

ID=49157870

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103935.4A HK1216002A1 (zh) 2013-03-11 2014-03-11 治疗动脉瘤性蛛网膜下出血并发症的组合物及其用途

Country Status (14)

Country Link
US (2) US10092524B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968166A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016512527A (cg-RX-API-DMAC7.html)
KR (1) KR101902319B1 (cg-RX-API-DMAC7.html)
CN (1) CN105324108A (cg-RX-API-DMAC7.html)
AU (1) AU2014248877A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015022218A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905327A1 (cg-RX-API-DMAC7.html)
GB (1) GB2528801A (cg-RX-API-DMAC7.html)
HK (1) HK1216002A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ629730A (cg-RX-API-DMAC7.html)
RU (1) RU2015143206A (cg-RX-API-DMAC7.html)
SG (1) SG11201507398XA (cg-RX-API-DMAC7.html)
WO (1) WO2014164904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
AU2012240131B2 (en) 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
JP2018522942A (ja) * 2015-05-29 2018-08-16 エッジ セラピューティクス インコーポレイテッド 視力障害を低減するための組成物及び方法
WO2017176914A1 (en) * 2016-04-07 2017-10-12 Edge Therapeutics, Inc. Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneurysmal subarachnoid hemorrhage
CN108403629B (zh) * 2018-04-26 2019-11-05 徐州医科大学 一种尼莫地平口服长效悬浮液及其制备方法
US12697299B2 (en) * 2019-05-07 2026-08-04 Yale University Maximizing distribution and minimizing washout of injectates in bone and method for enhanced aspirate extraction
WO2020235947A1 (ko) * 2019-05-22 2020-11-26 경북대학교 산학협력단 Cacb1 유래 펩타이드, Cacb1 유래 펩타이드의 변이체 및 이의 용도
US20210260334A1 (en) * 2020-02-20 2021-08-26 Postsurgical Therapeutics, Inc. Brain drug delivery system and method
WO2021262725A1 (en) * 2020-06-22 2021-12-30 Curelator, Inc. Systems and methods for segmentation of a user population based on time-based variations in biomarker levels
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
WO2022185235A1 (en) * 2021-03-03 2022-09-09 Crannmed Limited Alginate based particles as a temporary embolic agent
WO2025151741A1 (en) * 2024-01-10 2025-07-17 Brown David Donaldson Methods of treating migraine headache or tension headache with hyaluronic acid

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
CA2180526A1 (en) 1994-01-05 1995-07-13 Joseph C. Hogan, Jr. Method of identifying chemical compounds having selected properties for a particular application
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
AT404429B (de) 1995-06-09 1998-11-25 Immuno Ag Anti-plasma-antikörper-präparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
ATE318580T1 (de) 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
CA2296056A1 (en) 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
AU9596698A (en) 1997-10-15 1999-05-03 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
JP2000070366A (ja) 1998-09-02 2000-03-07 Arute:Kk 容器兼用注射器及び容器兼用注射器への凍結乾燥製剤の封入方法
US20050214227A1 (en) * 1999-03-08 2005-09-29 Powderject Research Limited Microparticle formulations for sustained-release of bioactive compounds
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
AU2607701A (en) 1999-12-29 2001-07-09 Regeneration Technologies, Inc. System for reconstituting pastes and methods of using same
JP2003520830A (ja) 2000-01-25 2003-07-08 エドワーズ ライフサイエンシーズ コーポレイション 再狭窄および吻合内膜過形成処置のための送達系
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002003406A (ja) 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
WO2003020208A2 (en) 2001-08-31 2003-03-13 Neuron Therapeutics, Inc. Treatment of neurologic hemorrhage
US20040235801A1 (en) 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
ATE470351T1 (de) 2001-11-22 2010-06-15 Japan Science & Tech Agency Nichtmenschliches tiermodell, das nicht auf eine immunopotenzierende synthetische verbindung anspricht
AU2003219922B2 (en) 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
TW200307011A (en) 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
DE60334983D1 (de) 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
US20060094643A1 (en) 2002-07-03 2006-05-04 Yuri Svirkin Compositions of hyaluronic acid and methods of use
US7713551B2 (en) 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
JP4092994B2 (ja) 2002-09-13 2008-05-28 ニプロ株式会社 プレフィルドシリンジキット
AU2003298749A1 (en) * 2002-11-26 2004-06-18 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
WO2005003180A2 (en) 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
US20070207211A1 (en) 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
AU2004259209A1 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
EP2514445B1 (en) 2003-10-22 2018-07-18 Encelle, Inc. Bioactive hydrogel compositions for the regeneration of connective tissue
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US8034762B2 (en) 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006084005A2 (en) 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US20090156481A1 (en) 2005-07-15 2009-06-18 Novo Nordisk Healthcare A/G Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy
GB0515492D0 (en) 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
EP1933837A4 (en) 2005-10-14 2009-07-15 Transform Pharmaceuticals Inc PHARMACEUTICAL LIQUID COMPOSITIONS OF NIMODIPIN
US20070203079A1 (en) 2005-11-21 2007-08-30 Caldwell Guy A Methods of using small molecule compounds for neuroprotection
WO2008087424A1 (en) 2007-01-18 2008-07-24 Reckitt Benckiser N.V. Dosage element and a method of manufacturing a dosage element
WO2008134541A2 (en) 2007-04-25 2008-11-06 Musculoskeletal Transplant Foundation Reinforced biological mesh for surgical reinforcement
US9005183B2 (en) 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US8252302B2 (en) 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
NZ599430A (en) 2007-06-11 2014-03-28 Loch Macdonald R A drug delivery system for the prevention of cerebral vasospasm
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US8569375B2 (en) 2008-08-22 2013-10-29 Reckitt Benckiser Healthcare (Uk) Limited Compositions
EP2331082B1 (en) 2008-09-11 2021-01-06 Evonik Corporation Solvent extraction microencapsulation with tunable extraction rates
CA2737484C (en) 2008-09-18 2017-10-10 Surmodics Pharmaceuticals, Inc. Microencapsulation process with solvent and salt
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
US20100189763A1 (en) 2009-01-23 2010-07-29 Heather Nettles Controlled release systems from polymer blends
JP2012515837A (ja) 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ, インコーポレイテッド 異なる非反復単位を有するポリマーを含むポリマー混合物、ならびにそれを作製および使用するための方法
US20100291027A1 (en) 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
US20110033463A1 (en) 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
JP5791629B2 (ja) 2009-12-22 2015-10-07 エボニック コーポレイションEvonik Corporation 微粒子を調製する乳剤基調プロセス、及び、プロセスで利用されるワークヘッド構造体
JP2013523752A (ja) 2010-03-29 2013-06-17 エボニック デグサ コーポレイション 局所投与部位における医薬組成物の保持改善のための組成物および方法
ES2646720T3 (es) 2011-02-11 2017-12-15 Edge Therapeutics, Inc. Composiciones y métodos para mejorar el pronóstico de un humano con hemorragia subaracnoidea
AU2012240131B2 (en) 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof

Also Published As

Publication number Publication date
BR112015022218A2 (pt) 2017-07-18
SG11201507398XA (en) 2015-10-29
US10092524B2 (en) 2018-10-09
GB2528801A (en) 2016-02-03
AU2014248877A1 (en) 2015-10-01
EP2968166A1 (en) 2016-01-20
KR101902319B1 (ko) 2018-09-28
EP2968166A4 (en) 2016-10-05
CA2905327A1 (en) 2014-10-09
GB201516997D0 (en) 2015-11-11
JP2016512527A (ja) 2016-04-28
US20130243864A1 (en) 2013-09-19
US20160324796A1 (en) 2016-11-10
RU2015143206A (ru) 2017-04-18
WO2014164904A1 (en) 2014-10-09
CN105324108A (zh) 2016-02-10
AU2014248877A8 (en) 2015-10-29
KR20150136084A (ko) 2015-12-04
NZ629730A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
AU2014248877A8 (en) Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
EP3313875A4 (en) Methods and compositions for treatment of symptoms associated with intracranial hemorrhage
IL258648A (en) Compositions and methods for reducing ice crystal formation
GB201317446D0 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
ZA201600453B (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
HK1209021A1 (en) Nanotherapeutics for drug targeting
IL262879A (en) Modified seraphins for the treatment of bleeding disorders
ZA201601634B (en) Composition comprising torasemide and baclofen for treating neurological disorders
EP3024497A4 (en) Methods and compositions for treating brain diseases
AU2014306716B2 (en) Compositions and methods for treating celiac sprue disease
EP2879617A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF EYE ARTERY CLOSURE
EP3294296A4 (en) Compositions and methods for assessing eye vasculature
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
EP2986113A4 (en) Compositions and methods for the treatment of brain injury
EP2989123A4 (en) METHODS AND COMPOSITIONS FOR TREATING COAGULATION DISORDERS
EP3122872A4 (en) Compositions and methods for treating type 1 and type 2 diabetes and related disorders
HK1202264A1 (en) Polymorph compositions, methods of making, and uses thereof
EP2982352A4 (en) Cerclage pessary containing progesterone for prolonged, sustained and continuous release, used to prevent premature birth
EP3310353A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES
WO2014194053A3 (en) Carbohydrate compounds for nutritional and therapeutic use
IL238415A0 (en) Compositions and methods for treating or preventing diseases or disorders associated with eif4e dysregulation
IL257452B (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
WO2015029035A8 (en) SELECTIVE INHIBITORS OF α2 ISOFORM OF Na,K-ATPase AND USE FOR REDUCTION OF INTRA-OCULAR PRESSURE
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases